SIPI-6360

The kilogram-scale synthesis of a D₂/5-HT_2A receptor dual antagonist (±)-SIPI 6360 (I) was developed as an alternative treatment for schizophrenia.Specifically, three conditions were modified and optimized, including the Vilsmeier conditions, to prepare quinoline 3 (III).In addition, the palladium-catalyzed hydrogenation was modified to synthesize dihydroquinolin-2(1H)-one 5 (V), and the reduction of β-chloroamide was altered to form 3-chloropropanamine 8 (VIII).Ultimately these improvements led to the preparation of a 1.5 kg of (±)-SIPI 6360 batch in eight steps with an overall yield of 34% and purity of 99.8%.